HL7® FHIR® Te Aho o Te Kahu, Cancer Control Agency Implementation Guide, published by Te Aho o Te Kahu, Cancer Control Agency. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7NZ/cca/ and changes regularly. See the Directory of published versions

• Narrative Content
• XML
• JSON
• TTL

: ESMO-MCBS Evaluation Form - TTL Representation

Active as of 2026-05-21

Raw ttl | Download

@prefix fhir: <http://hl7.org/fhir/> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

# - resource -------------------------------------------------------------------

 a fhir:CodeSystem ;
  fhir:nodeRole fhir:treeRoot ;
  fhir:id [ fhir:v "sact-esmo-mcbs-evaluation-form"] ; # 
  fhir:text [
fhir:status [ fhir:v "generated" ] ;
fhir:div [ fhir:v "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: CodeSystem sact-esmo-mcbs-evaluation-form</b></p><a name=\"sact-esmo-mcbs-evaluation-form\"> </a><a name=\"hcsact-esmo-mcbs-evaluation-form\"> </a><p>This  code system <code>https://standards.digital.health.nz/ns/sact-esmo-mcbs-evaluation-form</code> defines the following codes:</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td></tr><tr><td style=\"white-space:nowrap\">ST-1a<a name=\"sact-esmo-mcbs-evaluation-form-ST-1a\"> </a></td><td>Evaluation Form 1a: For RCTs evaluating new approaches to adjuvant therapy or new potentially curative therapies</td></tr><tr><td style=\"white-space:nowrap\">ST-1b<a name=\"sact-esmo-mcbs-evaluation-form-ST-1b\"> </a></td><td>Evaluation Form 1b: For single arm de-escalation studies in the adjuvant setting</td></tr><tr><td style=\"white-space:nowrap\">ST-2a<a name=\"sact-esmo-mcbs-evaluation-form-ST-2a\"> </a></td><td>Evaluation Form 2a: For therapies that are not likely to be curative with primary endpoint of OS</td></tr><tr><td style=\"white-space:nowrap\">ST-2b<a name=\"sact-esmo-mcbs-evaluation-form-ST-2b\"> </a></td><td>Evaluation Form 2b: For therapies that are not likely to be curative with primary endpoint PFS</td></tr><tr><td style=\"white-space:nowrap\">ST-2c<a name=\"sact-esmo-mcbs-evaluation-form-ST-2c\"> </a></td><td>Evaluation Form 2c: For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies</td></tr><tr><td style=\"white-space:nowrap\">ST-3<a name=\"sact-esmo-mcbs-evaluation-form-ST-3\"> </a></td><td>Evaluation Form 3: For single-arm studies in orphan diseases and for diseases with high unmet need when primary outcome is PFS or ORR</td></tr><tr><td style=\"white-space:nowrap\">HM-1a<a name=\"sact-esmo-mcbs-evaluation-form-HM-1a\"> </a></td><td>Evaluation Form 1a: For RCTs evaluating new approaches to new potentially curative therapies</td></tr><tr><td style=\"white-space:nowrap\">HM-1b<a name=\"sact-esmo-mcbs-evaluation-form-HM-1b\"> </a></td><td>Evaluation Form 1b: For single arm therapies with curative intent and de-escalation studies</td></tr><tr><td style=\"white-space:nowrap\">HM-2a<a name=\"sact-esmo-mcbs-evaluation-form-HM-2a\"> </a></td><td>Evaluation Form 2a: For therapies that are not likely to be curative with primary endpoint of OS</td></tr><tr><td style=\"white-space:nowrap\">HM-2b<a name=\"sact-esmo-mcbs-evaluation-form-HM-2b\"> </a></td><td>Evaluation Form 2b: For therapies that are not likely to be curative with primary endpoint PFS</td></tr><tr><td style=\"white-space:nowrap\">HM-2c<a name=\"sact-esmo-mcbs-evaluation-form-HM-2c\"> </a></td><td>Evaluation Form 2c: For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies</td></tr><tr><td style=\"white-space:nowrap\">HM-3<a name=\"sact-esmo-mcbs-evaluation-form-HM-3\"> </a></td><td>Evaluation Form 3: For single-arm studies in orphan diseases and for diseases with high unmet need when primary outcome is PFS or ORR</td></tr></table></div>"^^rdf:XMLLiteral ]
  ] ; # 
  fhir:url [
fhir:v "https://standards.digital.health.nz/ns/sact-esmo-mcbs-evaluation-form"^^xsd:anyURI ;
fhir:l <https://standards.digital.health.nz/ns/sact-esmo-mcbs-evaluation-form>
  ] ; # 
  fhir:version [ fhir:v "0.1.0"] ; # 
  fhir:name [ fhir:v "EsmoMcbsEvaluationForm"] ; # 
  fhir:title [ fhir:v "ESMO-MCBS Evaluation Form"] ; # 
  fhir:status [ fhir:v "active"] ; # 
  fhir:date [ fhir:v "2026-05-21T02:29:02+00:00"^^xsd:dateTime] ; # 
  fhir:publisher [ fhir:v "Te Aho o Te Kahu, Cancer Control Agency"] ; # 
  fhir:description [ fhir:v "The evaluation forms used in the ESMO Magnitude of Clinical Benefit Scale"] ; # 
  fhir:content [ fhir:v "complete"] ; # 
  fhir:count [ fhir:v "12"^^xsd:nonNegativeInteger] ; # 
  fhir:concept ( [
fhir:code [ fhir:v "ST-1a" ] ;
fhir:display [ fhir:v "Evaluation Form 1a: For RCTs evaluating new approaches to adjuvant therapy or new potentially curative therapies" ]
  ] [
fhir:code [ fhir:v "ST-1b" ] ;
fhir:display [ fhir:v "Evaluation Form 1b: For single arm de-escalation studies in the adjuvant setting" ]
  ] [
fhir:code [ fhir:v "ST-2a" ] ;
fhir:display [ fhir:v "Evaluation Form 2a: For therapies that are not likely to be curative with primary endpoint of OS" ]
  ] [
fhir:code [ fhir:v "ST-2b" ] ;
fhir:display [ fhir:v "Evaluation Form 2b: For therapies that are not likely to be curative with primary endpoint PFS" ]
  ] [
fhir:code [ fhir:v "ST-2c" ] ;
fhir:display [ fhir:v "Evaluation Form 2c: For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies" ]
  ] [
fhir:code [ fhir:v "ST-3" ] ;
fhir:display [ fhir:v "Evaluation Form 3: For single-arm studies in orphan diseases and for diseases with high unmet need when primary outcome is PFS or ORR" ]
  ] [
fhir:code [ fhir:v "HM-1a" ] ;
fhir:display [ fhir:v "Evaluation Form 1a: For RCTs evaluating new approaches to new potentially curative therapies" ]
  ] [
fhir:code [ fhir:v "HM-1b" ] ;
fhir:display [ fhir:v "Evaluation Form 1b: For single arm therapies with curative intent and de-escalation studies" ]
  ] [
fhir:code [ fhir:v "HM-2a" ] ;
fhir:display [ fhir:v "Evaluation Form 2a: For therapies that are not likely to be curative with primary endpoint of OS" ]
  ] [
fhir:code [ fhir:v "HM-2b" ] ;
fhir:display [ fhir:v "Evaluation Form 2b: For therapies that are not likely to be curative with primary endpoint PFS" ]
  ] [
fhir:code [ fhir:v "HM-2c" ] ;
fhir:display [ fhir:v "Evaluation Form 2c: For therapies that are not likely to be curative with primary endpoint other than OS or PFS or equivalent (non-inferiority) studies" ]
  ] [
fhir:code [ fhir:v "HM-3" ] ;
fhir:display [ fhir:v "Evaluation Form 3: For single-arm studies in orphan diseases and for diseases with high unmet need when primary outcome is PFS or ORR" ]
  ] ) . #